Genta Incorporated announced that the European Patent Office intends to grant two key patents related to the companyâ€™s intellectual property position on GenasenseÂ® (oblimersen sodium) Injection. These two patents will provide protection for compositions, sequences, and pharmaceutical uses of Genasense and related compounds that attack Bcl-2, the molecular target of Genasense action.
â€œGentaâ€™s patent estate related to Genasense is extensive, we have detailed plans for securing rapid approval in Europe with positive data this Fall,â€ commented Dr. Raymond P. Warrell, Jr., Gentaâ€™s Chief Executive Officer. â€œThe majority of patients enrolled into the AGENDA trial, a Phase 3 trial of Genasense in melanoma that completed accrual earlier this month, originated from Europe. The extended market protection offered by these patents comes at an especially favorable time in the productâ€™s lifecycle.â€